Kura Oncology, Inc.
KURA
$7.34
$0.050.69%
| Weiss Ratings | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.63 | |||
| Price History | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.52% | |||
| 30-Day Total Return | -11.03% | |||
| 60-Day Total Return | -24.64% | |||
| 90-Day Total Return | -58.79% | |||
| Year to Date Total Return | -15.44% | |||
| 1-Year Total Return | -65.11% | |||
| 2-Year Total Return | -40.18% | |||
| 3-Year Total Return | -55.49% | |||
| 5-Year Total Return | 13.80% | |||
| 52-Week High % Change | -68.95% | |||
| 52-Week Low % Change | 7.36% | |||
| Price | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $23.48 | |||
| 52-Week Low Price | $6.79 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Jul 16, 2024 | |||
| Valuation | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 588.70M | |||
| Enterprise Value | -122.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.02 | |||
| Earnings Per Share Growth | -2.90% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 11.79 | |||
| Price/Book (Q) | 1.38 | |||
| Enterprise Value/Revenue (TTM) | -2.27 | |||
| Price | $7.34 | |||
| Enterprise Value/EBITDA (TTM) | 0.63 | |||
| Enterprise Value/EBIT | 0.63 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 87.14M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 500 8800 | |||
| Address | 12730 High Bluff Drive San Diego, CA 92130 | |||
| Website | kuraoncology.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -358.54% | |||
| Profit Margin | -322.89% | |||
| Management Effectiveness | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.97% | |||
| Return on Equity | -- | |||
| Income Statement | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 53.88M | |||
| Total Revenue (TTM) | 53.88M | |||
| Revenue Per Share | $0.62 | |||
| Gross Profit (TTM) | -101.46M | |||
| EBITDA (TTM) | -192.35M | |||
| EBIT (TTM) | -193.20M | |||
| Net Income (TTM) | -173.98M | |||
| Net Income Avl. to Common (TTM) | -173.98M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 55.09% | |||
| EPS Diluted (TTM) | -2.02 | |||
| EPS Diluted Growth (Q YOY) | 60.14% | |||
| Balance Sheet | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 727.40M | |||
| Cash Per Share (Q) | $8.35 | |||
| Total Current Assets (Q) | 744.83M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 413.64M | |||
| Current Ratio (Q) | 9.463 | |||
| Book Value Per Share (Q) | $5.29 | |||
| Total Assets (Q) | 760.16M | |||
| Total Current Liabilities (Q) | 78.71M | |||
| Total Debt (Q) | 16.59M | |||
| Total Liabilities (Q) | 346.52M | |||
| Total Common Equity (Q) | 413.64M | |||
| Cash Flow | KURA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -101.59M | |||
| Cash from Financing (TTM) | 154.42M | |||
| Net Change in Cash (TTM) | 187.14M | |||
| Levered Free Cash Flow (TTM) | -60.61M | |||
| Cash from Operations (TTM) | 134.32M | |||
